Daiichi Sankyo

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Daiichi Sankyo and other ETFs, options, and stocks.

About DSNKY

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. 

CEO
Hiroyuki Okuzawa
CEOHiroyuki Okuzawa
Employees
19,765
Employees19,765
Headquarters
Tokyo, Tokyo
HeadquartersTokyo, Tokyo
Founded
2005
Founded2005
Employees
19,765
Employees19,765

DSNKY Key Statistics

Market cap
34.47B
Market cap34.47B
Price-Earnings ratio
19.06
Price-Earnings ratio19.06
Dividend yield
2.02%
Dividend yield2.02%
Average volume
566.45K
Average volume566.45K
High today
$18.90
High today$18.90
Low today
$17.80
Low today$17.80
Open price
$18.87
Open price$18.87
Volume
168.66K
Volume168.66K
52 Week high
$29.68
52 Week high$29.68
52 Week low
$17.80
52 Week low$17.80

DSNKY News

TipRanks 19h
Daiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data

Daiichi Sankyo Company ( (JP:4568) ) has shared an announcement. Daiichi Sankyo has released its consolidated financial reference data for the third quarter of...

Analyst ratings

94%

of 16 ratings
Buy
93.8%
Hold
6.3%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.